ClinicalTrials.gg
CompletedNCT06048887Updated Sep 21, 2023

Single and Multiple-Ascending Dose Study of CRN04894 in Healthy Volunteers

A Phase 1 interventional study of CRN04894 Oral Solution and Placebo Oral Solution in Healthy Volunteers, sponsored by Crinetics Pharmaceuticals Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by Crinetics Pharmaceuticals Inc. (part of Vertex Pharmaceuticals Incorporated) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2022, 4 years 7 months ago, and no results have been posted to the registry.
  • Registered 2 years 8 months after the study started (first participant enrolled Dec 2020, registered Sep 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A Phase 1, first-in-human, double-blind, randomized, placebo-controlled study to evaluate the safety of CRN04894 in healthy volunteers as well as the relationship between exposure and pharmacodynamic (PD) parameters.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Crinetics Pharmaceuticals Inc. is the lead sponsor of 19 studies on the registry; 3 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.

First submitted before Crinetics Pharmaceuticals Inc. became part of Vertex Pharmaceuticals Incorporated.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females must be either or surgically sterile; or using stable and permitted highly effective method of - use of oral hormonal contraceptives are not allowed during the study
  • Male subjects must be surgically sterile or agree to use highly effective form of contraception when sexually active with a female partner of child bearing potential
  • ACTH-stimulated serum cortisol high-dose ACTH stimulation test conducted at Screening

Exclusion criteria

Exclusion Criteria:

  • Use of topical, nasal, inhaled, or oral .
  • Use of any drug within the past 60 days.
  • Have a medically significant illness within 30 days prior to screening.
  • Use of prohibited prescribed or nonprescribed medications and/or nonmedications/alternative medicinal products.
  • Any condition that in the opinion of the investigator would jeopardize the subject's appropriate participation in this study.
  • Unstable psychological disorder ≤1 year prior to Screening.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Single Ascending Dose (Part 1)

    Drug: CRN04894 Oral Solution · Drug: Placebo Oral Solution

  • Experimental
    Multiple Ascending Dose (Part 2)

    Drug: CRN04894 Oral Solution · Drug: Placebo Oral Solution

Interventions

  • CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.

  • DrugPlacebo Oral Solution

    Placebo

06

What researchers measure

Primary outcomes

  1. Percentage of subjects with treatment-emergent adverse events

    Time frame: Part 1 - up to Day 8; Part 2 - up to Day 20

  2. Proportion of participants with a clinically significant safety laboratory observation

    Time frame: Part 1 - up to Day 8; Part 2 - up to Day 20

Secondary outcomes

  1. Pharmacokinetics (AUC)

    Assessment of the plasma area under the curve of CRN04894

    Time frame: Part 1 - up to Day 8; Part 2 - up to Day 20

  2. Pharmacokinetics (Cmax)

    Assessment of the maximum observed plasma concentration of CRN04894

    Time frame: Part 1 - up to Day 8; Part 2 - up to Day 20

  3. Pharmacokinetics (Tmax)

    Assessment of time to maximal CRN04894 concentration (Tmax)

    Time frame: Part 1 - up to Day 8; Part 2 - up to Day 20

  4. Pharmacokinetics (T1/2)

    Assessment of elimination half-life of CRN04894

    Time frame: Part 1 - up to Day 8; Part 2 - up to Day 20

Other outcomes

  1. Change in ACTH-stimulated serum cortisol

    Time frame: Part 1 - Day 1; Part 2 - Day 10

  2. Change in serum cortisol

    Time frame: Part 1 - up to Day 8; Part 2 - up to Day 20

07

Study locations

1 site
  • QPS-Miami Research Associates
    Miami, Florida 33143, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Apr 2022, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2023
First posted
Sep 21, 2023
StartActual
Dec 18, 2020
Primary completionActual
Apr 11, 2022
CompletionActual
Apr 11, 2022
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06048887
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Dec 18, 2020
Primary completion
Apr 11, 2022
Completion
Apr 11, 2022
Last update
Sep 21, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atumelnant

Start the discussion